Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women : a randomised controlled trial. / Hansen, Rebecka; Sommer, Veronika Markova; Pinborg, Anja; Krebs, Lone; Thomsen, Lars Lykke; Moos, Torben; Holm, Charlotte.
In: Archives of Gynecology and Obstetrics, Vol. 308, 2023, p. 1165–1173.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women
T2 - a randomised controlled trial
AU - Hansen, Rebecka
AU - Sommer, Veronika Markova
AU - Pinborg, Anja
AU - Krebs, Lone
AU - Thomsen, Lars Lykke
AU - Moos, Torben
AU - Holm, Charlotte
PY - 2023
Y1 - 2023
N2 - Purpose To compare the efficacy of intravenous (IV) iron (ferric derisomaltose) with oral iron (ferrous fumarate) in women 14-21 weeks pregnant with persistent iron deficiency (ferritinMethods In a single-centre, open-label, randomised controlled trial at a Danish hospital, women with persistent iron deficiency after routine oral iron treatment were allocated to receive 1000 mg IV iron (single-dose) or 100 mg elemental oral iron daily. Outcomes were assessed during an 18-week follow-up period. The primary endpoint was the proportion of nonanaemic (haemoglobin [Hb] >= 11 g/dL) women throughout follow-up. Other outcomes included changes in haematological parameters, patient-reported fatigue, and quality of life (QoL). Safety was assessed by recording adverse events.Results From July 2017 to February 2020, 100 women were randomised to IV iron and 101 to oral iron. Throughout followup, 91% of women were non-anaemic in the IV iron group compared with 73% in the oral iron group (18% difference [95% confidence interval 0.10-0.25]; p < 0.001). The mean Hb increase was significantly greater with IV iron versus oral iron at Weeks 6 (0.4 versus - 0.2 g/dL; p < 0.001), 12 (0.5 versus 0.1 g/dL; p < 0.001), and 18 (0.8 versus 0.5 g/dL; p= 0.01). Improvements in fatigue and QoL were greater with IV iron versus oral iron at Weeks 3 and 6. The incidence of treatment-related adverse events was comparable between treatment groups.Conclusion IV iron was superior in preventing anaemia compared with oral iron in pregnant women with persistent iron deficiency; biochemical superiority was accompanied by improved fatigue and QoL.
AB - Purpose To compare the efficacy of intravenous (IV) iron (ferric derisomaltose) with oral iron (ferrous fumarate) in women 14-21 weeks pregnant with persistent iron deficiency (ferritinMethods In a single-centre, open-label, randomised controlled trial at a Danish hospital, women with persistent iron deficiency after routine oral iron treatment were allocated to receive 1000 mg IV iron (single-dose) or 100 mg elemental oral iron daily. Outcomes were assessed during an 18-week follow-up period. The primary endpoint was the proportion of nonanaemic (haemoglobin [Hb] >= 11 g/dL) women throughout follow-up. Other outcomes included changes in haematological parameters, patient-reported fatigue, and quality of life (QoL). Safety was assessed by recording adverse events.Results From July 2017 to February 2020, 100 women were randomised to IV iron and 101 to oral iron. Throughout followup, 91% of women were non-anaemic in the IV iron group compared with 73% in the oral iron group (18% difference [95% confidence interval 0.10-0.25]; p < 0.001). The mean Hb increase was significantly greater with IV iron versus oral iron at Weeks 6 (0.4 versus - 0.2 g/dL; p < 0.001), 12 (0.5 versus 0.1 g/dL; p < 0.001), and 18 (0.8 versus 0.5 g/dL; p= 0.01). Improvements in fatigue and QoL were greater with IV iron versus oral iron at Weeks 3 and 6. The incidence of treatment-related adverse events was comparable between treatment groups.Conclusion IV iron was superior in preventing anaemia compared with oral iron in pregnant women with persistent iron deficiency; biochemical superiority was accompanied by improved fatigue and QoL.
KW - Iron deficiency
KW - Anaemia
KW - Pregnancy
KW - Intravenous iron
KW - HEALTH SURVEY
KW - ANEMIA
KW - CARBOXYMALTOSE
U2 - 10.1007/s00404-022-06768-x
DO - 10.1007/s00404-022-06768-x
M3 - Journal article
C2 - 36107229
VL - 308
SP - 1165
EP - 1173
JO - Archives of Gynecology and Obstetrics
JF - Archives of Gynecology and Obstetrics
SN - 0932-0067
ER -
ID: 320663897